国家医保局：商保创新药目录121个药品通用名通过形式审查

Group 1 - The National Healthcare Security Administration (NHSA) has released information regarding the preliminary review of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog adjustments, including the commercial insurance innovative drug catalog [1][2] - A total of 141 applications for the commercial insurance innovative drug catalog were received, with 121 drug names passing the preliminary review [1] - For the basic medical insurance catalog, 718 applications were received, involving 633 drug names, with 534 passing the preliminary review, indicating a significant increase from 249 in 2024 [1] Group 2 - The adjustment process includes several stages: enterprise application, preliminary review, expert evaluation, negotiation, and price consultation, with the preliminary review being the first step [2] - Passing the preliminary review only indicates that the drug meets the application criteria and qualifies for the next steps, not that it is included in the basic medical insurance or commercial insurance innovative drug catalog [2] - The NHSA acknowledged that some expensive drugs exceeding basic insurance coverage have passed the preliminary review, but their final inclusion depends on strict evaluation processes and successful negotiations [2]